Outcome following local injection of a liquid amnion allograft for treatment of equine tendonitis or desmitis – 100 cases

Hugh. R. Duddy1, Mike. J. Schoonover1* and Brent. A. Hague2

Abstract
Background: Tendon and ligament injuries are significant causes of loss of use and early retirement in performance horses. Amniotic fluid and tissue are excellent sources of growth factors and cytokines important in tendon and ligament healing. Thus, an equine-origin liquid amnion allograft (ELAA) may be beneficial in the treatment of equine tendonitis and desmitis. Objectives of this study were to report the outcome achieved (i.e. ability to return to work) for horses diagnosed with tendonitis or desmitis lesions treated with local injection of ELAA and to compare these outcomes to those reported for other regenerative medicine modalities.

Methods: A prospective, multi-center, non-blinded clinical trial was conducted. Equine veterinarians at 14 sites were selected to participate in the data collection for the trial. Criterion for inclusion was a horse presenting with lameness which was attributed to tendonitis or desmitis by diagnostic anesthesia and/or imaging. These horses were subsequently treated by local injection of the lesion with ELAA by the attending veterinarian. Standardized questionnaires describing each horse's signalment, discipline, ability to return to work, and any adverse events were completed and submitted by the attending veterinarian following a minimum of six months of follow-up. The current literature was reviewed to identify clinical studies reporting outcomes of equine tendonitis/desmitis lesions treated with other regenerative therapies. Contingency table analyses were performed comparing outcomes.

Results: Questionnaires for 100 horses with 128 tendonitis and desmitis lesions met the inclusion criteria. Of these, 72 horses with 94 lesions returned to or exceeded their original level of work, 10 horses with 13 lesions returned to work but could not perform to previous standards, and 18 horses with 20 lesions did not return to work as a result of the injury. No differences were observed when outcome of horses treated with ELAA were compared to those of similar studies using other regenerative therapies.

Conclusions: Treatment of tendonitis and desmitis lesions by local injection of ELAA resulted in similar outcomes for horses returning to previous level of performance as other regenerative modalities such as mesenchymal stem cells, platelet-rich plasma, and autologous conditioned serum; however, blinded placebo-controlled studies are indicated.

Keywords: Regenerative medicine, Horse, Tendon, Ligament

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
acute inflammatory phase characterized by pain, intralesional hemorrhage, and edema. Circulating inflammatory cells infiltrate the injury and release initial growth factors and cytokines. Growth factors and cytokines orchestrate biological processes throughout the healing process [1, 9]. The acute inflammatory response is followed by the proliferative phase where fibroblastic cells produce scar tissue comprised of far more type III collagen than the original tendon [1, 3, 10, 11]. The remodeling phase follows, resulting in the gradual transformation to more type I collagen though not to the same proportion as the original pre-injury tissue [1, 3, 10]. The end result is a tendon that lacks pre-injury biomechanical properties [1, 3, 9, 10].

Regenerative medicine seeks to restore structure and function to injured tissue [12–14]. The main components of regenerative therapies are scaffold, growth factors, and cells [12–14]. Current therapies include mesenchymal stem cells (MSCs) [7, 10, 12–17], platelet rich plasma (PRP) [12, 14, 15, 18–23], and autologous conditioned serum (ACS) [12, 14, 15, 24, 25]. Local injection of these therapies is common practice for horses with tendinous and ligamentous injuries. Amnion is considered a significant source of growth factors and cytokines important in tissue regeneration and healing [26, 27]. An equine origin, liquid amnion allograft (ELAA; RenoVō™, Equus Innovations) comprised of amnion and amniotic fluid is commercially available. Off-the-shelf availability of a regenerative modality could facilitate clinical use avoiding the time delay currently associated with autologous therapies that require sample collection and processing. To the authors’ knowledge, no published studies evaluate ELAA for the treatment of equine tendonitis or desmitis. The objective of this clinical trial was to evaluate the outcome (i.e. ability of horse to return to work) following local injection of ELAA for the treatment of tendinitis and desmitis lesions. Additionally, these outcomes were to be compared to those reported in published clinical studies using regenerative modalities such as MSCs, PRP, ACS, and gene therapies for the treatment of tendonitis and desmitis. Our hypothesis was that treatment of specific equine tendonitis and desmitis lesions with local injection of ELAA would result in outcomes comparable to horses with similar lesions treated with other regenerative modalities.

Methods
The design of the study was a non-blinded clinical trial. Experienced equine veterinarians at 14 hospitals (sites) were selected for participation in the study. An aseptically manufactured, commercially packaged, acellular, cryopreserved ELAA derived from equine amniotic tissues of healthy mares (RenoVō™, Equus Innovations) was used by all attending veterinarians. The ELAA was shipped frozen by the manufacturer to the sites with instructions to keep the product frozen at -80°C until use to preserve the beneficial proteins. Each site was provided with a calibrated -80°C portable freezer (Shuttle C Model ULT-25NE, Stirling Ultracold) to store the ELAA when received. The ELAA was provided in 1.5 mL and 3.0 mL volumes aseptically packaged in individual vials. Instructions for use directed the veterinarian to thaw the ELAA at room temperature and administer it locally in or around the lesion using strict aseptic technique including aseptic preparation of the administration site and the use of sterile gloves and administration paraphernalia. The volume of ELAA used to treat an individual lesion was left to the attending veterinarian’s discretion.

Client-owned horses were selected for enrollment and subsequent treatment with ELAA at the discretion of the attending veterinarian following examination, diagnosis and client education. Written informed client consent for treatment was obtained by the attending veterinarian prior to treatment. Criteria for inclusion in the study was defined as a horse displaying fore or hind limb lameness attributed to a specific diagnosis (lesion) of tendonitis or desmitis proven or supported by diagnostic anesthesia and/or imaging (ultrasound or magnetic resonance imaging) of the regional anatomy. Additionally, the identified lesion(s) must have been treated by local injection of ELAA with follow-up information available for a period of six months or more. All horses remained in the care of the owners throughout the study period.

For each horse enrolled, a standardized questionnaire was completed by the attending veterinarian which included the date of ELAA administration, ELAA product code and serial number, horse identification and signalment, diagnosis(es), duration of injury/lameness, initial and re-evaluation lameness grade [28], ability to return to work, adverse events, and product satisfaction (Additional file 1). The studied outcome measure was the ability of the horse to return to work following ELAA treatment. This was categorized as either returning to or exceeding the horse’s previous level of work, returning to work but not able to perform to the horse’s previous standards, or inability to return to work as a result of the injury and showing no improvement. Following review of the completed questionnaires, information from those meeting the above criteria was compiled and those deemed not to have met the study criteria or those missing pertinent information (diagnosis, initial lameness grade, or ability to return to work) were excluded. If a horse was administered ELAA for treatment of two or more separate lesions concurrently, each was considered a separate lesion.
Statistical analysis
The current literature was reviewed to identify clinical studies reporting outcomes of equine tendon and ligament lesions treated with regenerative medicine modalities including MSCs, PRP, ACS, and gene therapies. Contingency tables were used to calculate a Pearson Chi-square value for comparison of outcomes between these prior studies and those of the current study. For any comparison in which one or more cells contained less than 5 observations, a Fisher’s exact test was used. A \( p < 0.05 \) was considered significant.

Results
Outcome data
Nineteen veterinarians submitted 170 questionnaires describing their experiences with ELAA in horses. Following review, 100 questionnaires describing outcomes for 100 horses were determined to be complete and to have met the study’s inclusion criteria; only these were included in the assessment (Table 1). A total of 128 tendonitis or desmitis lesions were described in these 100 questionnaires: 78/100 questionnaires described local injection of a single lesion, 18/100 described local injection of two lesions, 2/100 described local injection of three lesions, and 2/100 questionnaires described local injection of four lesions. Two of the 100 horses were treated twice for the same lesions, one horse with a single lesion and the other with two lesions. Overall, 72/100 horses (72%) were reported to have either returned to or exceeded their previous level of work following local injection with the ELAA: 18/72 horses at less than three months, 40/72 horses at between three and six months, and 14/72 horses at greater than six months. Ten out of the 100 horses (10%) were reported to have returned to work but not perform to previous standards: 2/10 horses at less than three months, 6/10 horses at between three and six months, and 2/10 horses at greater than six months. Eighteen of the 100 horses (18%) were reported to have not returned to work as a result of the injury and showed no improvement. Duration of injury was reported on the questionnaire as <6 months for 51/100 horses, 6 months to 1 year for 19/100 horses, 1 to 2 years for 10/100 horses, and >2 years for 11/100 horses, while the duration of injury was not reported for 9/100 horses (Table 1). The individual lesions were categorized based on their anatomic location and ability of the horse to return to work (Table 2). Horses associated with 94 of the 128 lesions were reported to have either returned to their previous level of work or exceeded their previous level of work: horses associated with 20/94 lesions at less than three months, 53/94 lesions at between three and six months, and 21/94 lesions at greater than six months. Horses associated with 13 of the 128 lesions were reported to have returned to work but not perform to previous standards: horses associated with 2/13 lesions at less than three months, 6/13 lesions at between three and six months, and 5/13 lesions at greater than six months. Horses associated with 21 of the 128 lesions were reported to have not returned to work as a result of the injury and showed no improvement.

On 92 of 100 questionnaires, the attending veterinarians reported they were satisfied with both the ELAA and the response to therapy. Seventy-two of these 92 questionnaires reported the horse to have returned to or exceeded their previous level of work, 10/92 reported the horse to have returned to work but not perform to previous standards, and 10/92 reported the horse to have not returned to work as a result of the injury and showed no improvement. Six of 100 questionnaires indicated that the attending veterinarian was not satisfied and reported the horse to have not returned to work as a result of the injury and showed no improvement. A satisfaction response was not documented on 2/100 questionnaires.

Comparisons to historical work
The outcomes observed of the horses in the current study were compared to published, peer-reviewed clinical studies that described return to work following treatment with other regenerative therapies (Table 3). For some lesion types (deep digital flexor (DDF) tendonitis of the foot/pastern region, collateral ligament desmitis of the distal interphalangeal joint (CLD-DIPJ), and distal sesamoidean desmitis), previous work using regenerative modalities could not be identified. For these lesion types, historical work using conventional therapies was used for comparison (Table 3). No difference in outcome was observed with any comparison except when CLD-DIPJ outcomes of the current study were compared to those reported by Gutierrez-Nibeyro et al. [29] \( (p = 0.03) \). This report [29] described the long-term outcome of 20 horses diagnosed with CLD-DIPJ treated with a variety of modalities with 12 of 20 (60%) horses returning to and maintaining their previous level of exercise for at least
|                          | Returned to or exceeded previous level of work | Returned to work but could not perform to previous standards | No return to work as a result of the injury and no improvement |
|--------------------------|----------------------------------------------|-------------------------------------------------------------|---------------------------------------------------------------|
| **Age**                  |                                              |                                                             |                                                               |
| ≤ 3 years                | 4                                             | 0                                                          | 3                                                            |
| 4 to 10 years            | 40                                            | 6                                                          | 9                                                            |
| ≥ 11 years               | 26                                            | 4                                                          | 5                                                            |
| ND                       | 2                                             | 0                                                          | 1                                                            |
| **Weight**               |                                              |                                                             |                                                               |
| < 500 kg                 | 8                                             | 3                                                          | 2                                                            |
| 500 – 800 kg             | 59                                            | 7                                                          | 15                                                           |
| > 800 kg                 | 3                                             | 0                                                          | 0                                                            |
| ND                       | 2                                             | 0                                                          | 0                                                            |
| **Breed**                |                                              |                                                             |                                                               |
| AQHA/APHA                | 38                                            | 2                                                          | 17                                                           |
| Arabian/½ Arabian         | 17                                            | 3                                                          | 0                                                            |
| Warmblood                | 9                                             | 1                                                          | 0                                                            |
| Thoroughbred             | 2                                             | 2                                                          | 1                                                            |
| Other                    | 4                                             | 2                                                          | 0                                                            |
| ND                       | 2                                             | 0                                                          | 0                                                            |
| **Sex**                  |                                              |                                                             |                                                               |
| Stallion                 | 4                                             | 0                                                          | 0                                                            |
| Mare                     | 31                                            | 4                                                          | 6                                                            |
| Gelding                  | 36                                            | 6                                                          | 12                                                           |
| ND                       | 1                                             | 0                                                          | 0                                                            |
| **Discipline**           |                                              |                                                             |                                                               |
| Western Performance      |                                              |                                                             |                                                               |
| Barrel racing            | 14                                            | 1                                                          | 4                                                            |
| Roping                   | 5                                             | 1                                                          | 4                                                            |
| Cutting                  | 4                                             | 0                                                          | 3                                                            |
| Reining                  | 3                                             | 0                                                          | 4                                                            |
| Not specified            | 2                                             | 0                                                          | 0                                                            |
| Show                     | 22                                            | 4                                                          | 1                                                            |
| **Sport**                |                                              |                                                             |                                                               |
| Racing—TB                | 2                                             | 2                                                          | 1                                                            |
| Racing—Other             | 4                                             | 0                                                          | 0                                                            |
| Hunter/jumper            | 6                                             | 2                                                          | 0                                                            |
| Dressage                 | 2                                             | 0                                                          | 0                                                            |
| Not specified            | 1                                             | 0                                                          | 0                                                            |
| Other                    | 2                                             | 0                                                          | 1                                                            |
| ND                       | 5                                             | 0                                                          | 0                                                            |
| **Location of Injury**   |                                              |                                                             |                                                               |
| Fore                     | 47                                            | 6                                                          | 13                                                           |
| Hind                     | 25                                            | 4                                                          | 5                                                            |
| **Pre-Treatment Llameness Grade** |          |                                                             |                                                               |
| 1                        | 7                                             | 0                                                          | 3                                                            |
| 2                        | 27                                            | 1                                                          | 2                                                            |
| 3                        | 33                                            | 6                                                          | 11                                                           |
| 4                        | 5                                             | 3                                                          | 2                                                            |
| **Duration of Injury**   |                                              |                                                             |                                                               |
| < 6 months               | 37                                            | 4                                                          | 10                                                           |
| 6 Months—1 Year          | 13                                            | 3                                                          | 3                                                            |
| 1—2 years                | 6                                             | 1                                                          | 3                                                            |
| > 2 years                | 10                                            | 1                                                          | 0                                                            |
| ND                       | 6                                             | 1                                                          | 2                                                            |

ND Not documented, TB Thoroughbred
Table 2  Outcome of 128 tendonitis/desmitis lesions in 100 horses treated with an equine origin, liquid amnion allograft

| Lesion                      | Returned to or exceeded previous level of work | Returned to work but could not perform to previous standards | No return to work as a result of the injury and no improvement |
|-----------------------------|-----------------------------------------------|--------------------------------------------------------------|---------------------------------------------------------------|
| Suspensory branch desmitis  |                                               |                                                              |                                                               |
| All                         | 25 (66%)                                      | 4 (10%)                                                     | 9 (24%)                                                       |
| Fore                        | 16 (73%)                                      | 0 (0%)                                                      | 6 (27%)                                                       |
| Hind                        | 9 (56%)                                       | 4 (25%)                                                     | 3 (19%)                                                       |
| Proximal suspensory desmitis|                                               |                                                              |                                                               |
| All                         | 11 (73%)                                      | 1 (7%)                                                      | 3 (20%)                                                       |
| Fore                        | 5 (83%)                                       | 1 (17%)                                                     | 0 (0%)                                                        |
| Hind                        | 6 (67%)                                       | 0 (0%)                                                      | 3 (33%)                                                       |
| DDF tendonitis – foot/pastern region |                                               |                                                              |                                                               |
| All                         | 15 (68%)                                      | 3 (14%)                                                     | 4 (18%)                                                       |
| Fore                        | 12 (66%)                                      | 3 (17%)                                                     | 3 (17%)                                                       |
| Hind                        | 3 (75%)                                       | 0 (0%)                                                      | 1 (25%)                                                       |
| DDF tendonitis – cannon region |                                              |                                                              |                                                               |
| All                         | 8 (100%)                                      | 0 (0%)                                                      | 0 (0%)                                                        |
| Fore                        | 5 (100%)                                      | 0 (0%)                                                      | 0 (0%)                                                        |
| Hind                        | 3 (100%)                                      | 0 (0%)                                                      | 0 (0%)                                                        |
| SDF tendonitis              |                                               |                                                              |                                                               |
| All                         | 10 (67%)                                      | 2 (13%)                                                     | 3 (20%)                                                       |
| Fore                        | 8 (62%)                                       | 2 (15%)                                                     | 3 (23%)                                                       |
| Hind                        | 2 (100%)                                      | 0 (0%)                                                      | 0 (0%)                                                        |
| SDF-AL desmitis             |                                               |                                                              |                                                               |
| Fore                        | 1 (50%)                                       | 1 (50%)                                                     | 0 (0%)                                                        |
| Collateral desmitis – coffin joint |                                              |                                                              |                                                               |
| Fore                        | 9 (90%)                                       | 1 (10%)                                                     | 0 (0%)                                                        |
| Collateral desmitis—Other   |                                               |                                                              |                                                               |
| All                         | 3 (60%)                                       | 1 (20%)                                                     | 1 (20%)                                                       |
| Fore                        | 2 (67%)                                       | 0 (0%)                                                      | 2 (20%)                                                       |
| Hind                        | 1 (50%)                                       | 1 (50%)                                                     | 0 (0%)                                                        |
| Straight sesamoidean desmitis |                                              |                                                              |                                                               |
| All                         | 6 (86%)                                       | 0 (0%)                                                      | 1 (14%)                                                       |
| Fore                        | 4 (80%)                                       | 0 (0%)                                                      | 1 (20%)                                                       |
| Hind                        | 2 (100%)                                      | 0 (0%)                                                      | 0 (0%)                                                        |
| Oblique sesamoidean desmitis |                                              |                                                              |                                                               |
| All                         | 4 (100%)                                      | 0 (0%)                                                      | 0 (0%)                                                        |
| Fore                        | 2 (100%)                                      | 0 (0%)                                                      | 0 (0%)                                                        |
| Hind                        | 2 (100%)                                      | 0 (0%)                                                      | 0 (0%)                                                        |
| Patellar desmitis           |                                               |                                                              |                                                               |
| All                         | 2 (100%)                                      | 0 (0%)                                                      | 0 (0%)                                                        |

DDF Deep digital flexor, SDF Superficial digital flexor, AL Accessory (check) ligament

three months while eight (40%) were described to have a poor outcome.

Discussion
This multi-center clinical trial represents the first study to evaluate local injection of ELAA for treatment of equine tendonitis and desmitis, and reports that 72 of 100 (72%) treated horses returned to or exceeded their previous level of work after at least six months following treatment. No significant difference was identified comparing these results to a similar report describing the outcome of 99 horses with tendon and ligament injuries treated with local injection of a PRP preparation, although significance of superiority for PRP was approached ($p=0.06$). In that report [20], 81% of the horses returned to their previous use, 12% had clinical
improvement but could not perform at the previous level, and 7% were classified as failures (Table 3). In addition to the regenerative modality used, differences in the type and location of lesions, as well as the breed or discipline of horses could account for the differences in outcome percentages between this report [20] and the current study. Outcomes from another controlled clinical study evaluating local injection of MSCs and PRP for the treatment of tendinitis and desmitis lesions in the cannon region of 23 horses treated with MSCs and PRP [16] were not different from those of the current study ($p = 0.2$).

The most common lesion in the current study was categorized as suspensory branch desmitis (SBD), representing 38 of the 128 (30%) lesions reported. A prior case series described 11 horses with 18 SBD lesions treated with a single intra-lesional injection of PRP reported that five horses (45%) returned to their previous level of work within three months [21]. In another study, 22 warmblood sport horses were treated for SBD using intra-lesional allogeneic umbilical cord-derived MSCs resulting in 15 (68%) had returning to at least the same level of work after six months or more [17]. In the current study, 25 of 38 (66%) SBD lesions were associated with horses that either returned to or exceeded their previous level of work following local injection of ELAA [1]. Outcomes reported in these prior studies [17, 21] compared to those of the current study were not different ($p = 0.4$), thus treatment with ELAA should result in similar outcomes for horses with SBD.

In the current study, proximal suspensory desmitis (PSD) lesions accounted for 15 (12%) of the lesions, and 73% of those were associated with horses that either returned to or exceeded their previous level of work following local injection of ELAA. In a previous study,

| Lesion type/ location | Returned to or exceeded previous level of work | Returned to work but could not perform to previous standards | No return to work as a result of the injury and no improvement | p value |
|-----------------------|-----------------------------------------------|-------------------------------------------------------------|---------------------------------------------------------------|---------|
| Current study All     | 72                                            | 10                                                          | 18                                                            | 0.06    |
| Scala et al. 2014 [20]| 81                                            | 12                                                          | 7                                                             |         |
| Current study Cannon region | 54                                            | 22                                                          | 0.2                                                          |         |
| Renzi et al. 2013 [16]| 13                                            | 10                                                          | 7                                                             | 0.4     |
| Current study SBD     | 20                                            | 10                                                          | 0.5                                                           |         |
| Casteljns et al. 2011 [21]| 5                                            | 6                                                           | 0.3                                                           |         |
| Van Loon et al. 2014 [17]| 15                                           | 7                                                           | 0.2                                                           |         |
| Current study PSD     | 9                                             | 4                                                           | 0.04                                                          |         |
| Easter et al. 2014 [25]| 215                                           | 56                                                          | 0.5                                                           |         |
| Current study SDFT    | 9                                             | 5                                                           | 0.3                                                           |         |
| Zuffova et al. 2013 [22]| 14                                            | 8                                                           | 0.5                                                           |         |
| Geburek et al. 2016 [23]| 8                                             | 2                                                           | 0.3                                                           |         |
| Witte et al. 2011 [30]| 21                                            | 13                                                          | 0.2                                                           |         |
| Van Loon et al. 2014 [17]| 20                                           | 23                                                          | 0.2                                                           |         |
| Current study DDFT—cannon | 8                                             | 0                                                           | 0.2                                                           |         |
| Van Loon et al. 2014 [17]| 4                                             | 2                                                           | 0.2                                                           |         |
| Current study DDFT—foot/ pastern | 12                                           | 6                                                           | 0.2                                                           |         |
| *Smith et al. 2007 [31]| 9                                             | 11                                                          | 0.04                                                          |         |
| Current study DIPJ-CD | 7                                             | 1                                                           | 0.5                                                           |         |
| *Gutierrez-Hibeyro et al. 2009 [29]| 8                                           | 12                                                          | 0.5                                                           |         |
| Current study DSD     | 9                                             | 1                                                           | 0.3                                                           |         |
| *Sampson et al. 2007 [32]| 16                                           | 5                                                           | 0.5                                                           |         |
| *Schneider et al. 2003 [33]| 6                                            | 3                                                           | 0.5                                                           |         |

SBD Suspensory branch desmitis, PSD Proximal suspensory desmitis, DDFT Deep digital flexor tendon, SDFT Superficial digital flexor tendon, DIPJ-CD Distal interphalangeal joint collateral desmitis, DSD Distal sesamoidean desmitis

* Denotes work describing outcomes of lesions treated with conventional therapies
107 of 127 (84%) horses with forelimb PSD and 108 of 144 (75%) horses with hindlimb PSD were treated with a series of three peri-ligamentous injections of ACS, entered full training by 110 days from the initial injection, and had no recurrence of lameness after a month of training [25]. In the current study, five of six (83%) forelimb PSD lesions and six of nine (67%) hindlimb PSD lesions were associated with horses that either returned to or exceeded their previous level of work. Although the current study evaluated a smaller population, differences in outcome between this previous study [25] and the current study were not identified \((p=0.5)\), thus treatment with ELAA should result in similar outcomes for horses with PSD.

Superficial digital flexor (SDF) tendonitis accounted for 15 (12%) of the lesions in the current study. A case series of 22 racing Thoroughbreds with SDF tendonitis of varying severity reported that 64% of horses returned to racing following intra-lesional injection with PRP [22]. In a controlled clinical trial of 20 horses with forelimb SDF tendonitis, 8 of 10 (80%) horses treated with intra-lesional injection of PRP were performing at their previous level or higher 12 months post-injury while only 6 of 10 (60%) control horses shared that success [23]. A case series of 40 racing Thoroughbreds with SDF tendonitis treated with a series of four or five intra-lesional injections of insulin-like growth factor-type 1 reported that 21 of 34 (62%) horses for which race data were available raced at least once after treatment [30]. Additionally, 23 warmblood sport horses treated with intra-lesional injection of allogeneic umbilical cord-derived MSCs for SDF tendonitis resulted in 20 (87%) of these horses returning to at least the same level of work at least six months following treatment [17]. In the current study, 67% of the SDF tendonitis lesions treated with local injection of ELAA were associated with horses that returned to or exceeded their previous level of work. The range of success rates reported in these previous reports [17, 22, 23, 30] and the current study may be explained by differences in number, breed and discipline of the horses as well as the location (fore vs hind, proximal vs. distal) and severity of the lesions. Nonetheless, differences in outcome between these previous studies [17, 22, 23, 30] and the current study were not identified \((p=0.3)\), thus treatment with ELAA should result in similar outcomes for horses with SDF tendonitis.

In the current study, DDF tendonitis lesions accounted for 30 of the 128 (20%) lesions and were categorized anatomically as either cannon region or foot/pastern region. All 8 DDF tendonitis lesions in the cannon region as well as 15 of 22 (68%) in the foot/pastern region were associated with horses returning to or exceeding their previous level of work. A study treating six warmblood sport horses with intra-lesional injection of allogeneic umbilical cord-derived MSCs for DDF tendonitis reported that four of these horses (67%) returned to their previous level of work six or more months post-treatment [17], a rate not different \((p=0.2)\) from that of the current study. A review of the current literature could find no reports evaluating the use of regenerative modalities in the treatment of DDF tendonitis of the foot/pastern region exclusively. A retrospective case study of 20 horses with 22 DDF tendonitis lesions treated with endoscopic debridement and/or navicular suspensory desmotomy reported that only nine (45%) returned to pre-treatment performance levels after six or more months [31]. Comparing the outcomes of this report [31] to those of the current study (67% success rate) did not identify a difference \((p=0.2)\) treating similar lesions with ELAA. The low number of horses in both reports could account for the inability to detect a significant difference, and further research using ELAA to treat DDF tendonitis in the foot pastern region may be warranted.

The current report includes 10 horses diagnosed with CLD-DIPJ with 9 of these (90%) returning to or exceeding their previous level of work. This outcome data was better \((p=0.03)\) than that reported by Gutierrez-Nibeyro et al. [29] who utilized a variety of treatment modalities. Interestingly, one horse in that report was treated with intra-lesional injection of a urinary bladder matrix powder, but the outcome of that specific horses was not described [29]. Based on these outcome data, treatment of DIPJ-CD with ELAA may be warranted but blinded, controlled studies are indicated.

The current study also describes treatment of other collateral (5), distal sesamoidean (11), SDF accessory (2), and patellar (2) desmitis lesions with local injection of ELAA. A search of the current literature found very few reports describing long-term outcomes of horses diagnosed with these desmopathies with none evaluating the use of regenerative modalities for treatment. A previous study described 27 horses diagnosed with desmitis of the oblique (18), straight (3), or both (6) sesamoidean ligaments (10 forelimb, 17 hindlimb) treated with various non-regenerative modalities in addition to rest and rehabilitation [32]. Of the 21 horses available for follow-up, 16 (76%) were competing at the same or better level of performance [32]. Another study reported nine cases of straight sesamoidean desmitis (5 forelimb, 4 hindlimb) with six (67%) able to return to their intended use following primarily rest and rehabilitation for six months although four were treated surgically [33]. In the current report, six of seven (86%) horses diagnosed with straight sesamoidean desmitis and all four horses diagnosed with oblique sesamoidean desmitis returned to or exceeded their previous level of work following local injection of...
ELAA, however, these rates were not different ($p = 0.5$) than previously reported using conventional therapies [32, 33]. In a prior report, six of eight (75%) horses suffering from SDF accessory desmitis returned to their previous level of performance within six months following anti-inflammatory injection of the carpal sheath and rest [34]. Both of the horses diagnosed with SDF accessory desmitis in the current study returned to or exceeded their previous level of work following local injection of with ELAA. In a study of nine clinical cases of patellar desmitis, five were treated with rest and rehabilitation, three were treated surgically, and one was euthanized [35]. Of those nine, only one was able to return to its former level of competition [35]. Both cases of patellar desmitis in the current report returned to or exceeded their previous level of work following local injection of with ELAA. It is the authors’ opinion that the results presented in the current study support the use of local injection of ELAA for these desmopathies.

In the current study, the attending veterinarians reported local adverse reactions in 13% of horses following injection of ELAA. Although most of the events were transient swelling and redness, there were four reports of increase in lameness. In all four cases, the increase in lameness was reported to have resolved within 72 h with non-steroidal anti-inflammatory treatment. In a prior report, a local injection site reaction rate of 4.35% was reported for local injection of allogenic MSCs in 164 horses with 230 lesions, which included 208 tendon or ligament lesions [36]. The disparity in local adverse reaction rate between this report [36] and the current study could relate to the difference in study design or the regenerative product used. Additionally, transient local adverse reaction rates as high as 12% are reported following injection of sodium hyaluronate [37].

The attending veterinarian reported satisfaction with the ELAA product in 92 of 100 horses, indicating an overall positive experience. Interestingly, the attending veterinarian reported satisfaction in 10 horses that failed to show improvement following local injection of ELAA. Reasons for this may be that improvement was not expected due to the severity of the lesion or satisfaction referred to the ELAA product’s availability and ease of administration.

Limitations of the current study include the non-blinded design and the lack of a control group. The longest duration of follow-up was described as 6 months or more, thus some horses many have been evaluated at 6 months, while others may have been evaluated several weeks to months later. Having more precise follow-up periods would have allowed for more uniform reporting of outcomes. In addition, a longer duration of follow-up, perhaps 12 months or more, may have provided relevant information. The number of attending veterinarians likely introduced variability in patient selection and exact treatment methodologies (volume of ELAA injected per lesion, ELAA administration technique, rehabilitation program, adjunct therapies, etc.) and outcome measures utilized; however, the design of the current study did not include collection of these potential variables. Additionally, some of the specific lesion categories were low in numbers and may not represent an appropriate sample size, thus making interpretation difficult.

**Conclusions**

Results of this clinical trial indicate that local injection of ELAA achieves comparable rates of return to previous level of work as other regenerative modalities such as MSCs, PRP and ACS in horses diagnosed with tendonitis or desmitis. However, blinded, placebo-controlled studies focusing on specific lesion types are indicated to more accurately evaluate the usefulness of local injection of ELAA for the treatment of equine tendonitis or desmitis.

**Abbreviations**

ACS: Autologous conditioned serum; DIFI-CD: Distal interphalangeal joint collateral desmitis; DDF: Deep digital flexor; ELAA: Equine-origin, liquid amnion allograft; MSC: Mesenchymal stem cells; PRP: Platelet rich plasma; PSD: Proximal suspensory desmitis; SBD: Suspensory branch desmitis; SDF: Superficial digital flexor.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12917-022-03480-5.

**Additional file 1.** Veterinarian questionnaire used to gather data following injection of a liquid amnion allograft for the treatment of equine tendonitis or desmitis.

**Acknowledgements**

The authors would like to thank Jared D. Taylor, DVM, MPH, PhD, DACVIM (LA), DACVP for performing the statistical analyses. The authors would also like to thank Drs. Josh Blyden, Jessica Bush, Nathan Canada, Jesse Clement, Alan Donnell, Tim Eastman, Reese Hand, Tommy Hays, Brad Hill, Cliff Horns, Lauren Lamb, Mike Major, Shelby Matz, Garrett Metcalf, Krystle O’Cull, Cameron Stoudt, Andy Walker, Ty Wallis, and Chad Zubrod for their assistance enrolling horses and submitting completed questionnaires.

**Authors’ contributions**

All authors (HRD, MJS, BAH) contributed to study design, study execution, data analysis and interpretation, and final approval of the submitted manuscript and have agreed both to be personally accountable for the author’s own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature. HRD and MJS wrote the manuscript.

**Funding**

The liquid amnion allograft used in this study was provided to the sites for use in enrolled horses at a discounted cost by the manufacturer, Equus Innovations.
 Availability of data and materials
The data that supports the findings of this study are available upon request of the corresponding author. The data is not publicly available due to client/patient privacy restrictions.

Declarations

Ethics approval and consent to participate
No human participants have been involved. No ethical approval was obtained because all patients had naturally occurring disease and all treatments were performed for the direct benefit of the patient. Following consultation about the study design, written informed client consent was obtained for treatment of all horses.

Consent for publication
Not applicable.

Competing interests
MJRS and BAH have consulting agreements with Equus Innovations. Their responsibilities are to serve as medical experts on issues pertaining to products, collaborate with personnel and external parties in the selection, construction and implementation of clinical trials to evaluate performance of products, participate in product design, development, and testing and engage with stakeholders on a peer-to-peer basis regarding product use, characteristics and potential for expanded clinical indications. Additionally, BAH is a minority shareholder in Equus innovations. HRD has no conflicts of interest to declare.

Author details
1 Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Oklahoma State University, Stillwater, OK, USA. 2 Oakridge Equine Hospital, Edmond, OK, USA.

Received: 16 August 2020 Accepted: 19 October 2022
Published online: 07 November 2022

References

1. Dahlgren LA. Pathobiology of tendon and ligament injuries. Clin Tech Equine Pract. 2007;6:168–73.
2. Denoix J-M. Functional anatomy of tendons and ligaments in the distal limbs (manus and pes). Vet Clin North Am Equine Pract. 1994;10:273–322.
3. Dowling BA, Dart AJ, Hodgson DR, Smith RKW. Superficial digital flexor tendonitis in the horse. Equine Vet J. 2000;32:369–78.
4. Ely ER, Avella CS, Price JS, Smith RKW, Wood JLN, Verheyen KLP. Descriptive epidemiology of fracture, tendon and suspensory ligament injuries in National Hunt racehorses in training. Equine Vet J. 2009;41:372–8.
5. Nixon AJ, Dahlgren LA, Haupt JL, Yeager AE, Ward DL. Effect of adipose-derived nucleated cell fractions on tendon repair in horses with collagenase-induced tendonitis. Am J Vet Res. 2008;69:928–37.
6. O’Sullivan CB. Injuries of the flexor tendons: focus on the superficial digital flexor tendon. Clin Tech Equine Pract. 2007;6:189–97.
7. Smith RKW, Webbon PM. Harnessing the stem cell for the treatment of tendon injuries: heralding a new dawn? Br J Sports Med. 2005;39:582–4.
8. Thorpe CT, Clegg PD, Birch HL. A review of tendon injury: Why is the equine superficial digital flexor tendon most at risk? Equine Vet J. 2010;42:174–80.
9. Durham S, Stewart M. Cellular and molecular factors influencing tendon repair. Tissue Eng Part B Rev. 2017;23:307–17.
10. Richardson LE, Duddia J, Clegg PD, Smith R. Stem cells in veterinary medicine – attempts at regenerating equine tendon after injury. Trends Biotechnol. 2007;25:409–16.
11. Watkins JP, Auer JA, Gay S, Morgan SJ. Healing of surgically created defects in the equine superficial digital flexor tendon: collagen-type transformation and tissue morphologic reorganization. Am J Vet Res. 1985;46:2091–6.
12. Fortier LA, Smith RKW. Regenerative medicine for tendinous and ligamentous injuries of sport horses. Vet Clin North Am Equine Pract. 2008;24:191–201.
13. Lopez MJ, Jarazo J. State of the art: Stem cells in equine regenerative medicine. Equine Vet J. 2015;47:145–54.
14. Ortved KF. Regenerative medicine and rehabilitation for tendinous and ligamentous injuries in sport horses. Vet Clin North Am Equine Pract. 2018;34:359–73.
15. Schnabel LV, Boone L, Peroni JF. Regenerative medicine. In: Auer JA, Stick JA, Kummerle JM, Prange T, editors. Equine Surgery. 5th ed. St Louis: W.B. Saunders; 2019. p. 104–22.
16. Renzi S, Riccò S, Dotti S, Carlin S, Patruno M, Cinotti S, Ferrari M. Autologous bone marrow mesenchymal stromal cells for regeneration of injured equine ligaments and tendons: A clinical report. Res Vet Sci. 2013;95:272–7.
17. Van Loon VJF, Scheffer CJW, Genn HJ, Hoogendoorn AC, Greve JW. Clinical follow-up of horses treated with allogeneic equine mesenchymal stem cells derived from umbilical cord blood for different tendon and ligament disorders. Vet Q. 2014;34:92–7.
18. Romagnoli N, Rinnovati R, Ricciardi G, Lamberti C, Spinella G, Spadari A. Clinical evaluation of intralesional injection of platelet-rich plasma for the treatment of proximal suspensory ligament desmitis in horses. J Equine Vet Sci. 2015;35:141–6.
19. Waiselau M, Sutter WW, Genovesi RL, Bertone AL. Intralesional injection of platelet-rich plasma followed by controlled exercise for treatment of midbody suspensory ligament desmitis in Standardbred racehorses. J Am Vet Med Assoc. 2008;232:1515–20.
20. Scala M, Lenarduzzi S, Spagnolo F, Trapasso M, Ottonello C, Muraglia A, Barla A, Squillario M, Strada F. Regenerative medicine for the treatment of tendo-desmotic injuries of the equine. a series of 150 horses treated with platelet-derived growth factors. In: Vivo. 2014;28:1119–23.
21. Castelijns G, Crawford A, Schaffer J, Ortolano GA, Beauregard T, Smith RKW. Evaluation of a filter-prepared platelet concentrate for the treatment of suspensory branch injuries in horses. Vet Comp Orthop Trauma-tol. 2011;24:363–9.
22. Zuffova K, Krivova S, Zert Z. Platelet-rich plasma treatment of superficial digital flexor tendon lesions in racing Thoroughbreds. Vet Med. 2013;58:230–9.
23. Geburek F, Gaus M, van Schie HTM, Rohn K, Stadler PM. Effect of intralesional platelet-rich plasma (PRP) treatment on clinical and ultrasonographic parameters in equine naturally occurring superficial digital flexor tendinopathies – a randomized prospective controlled clinical trial. BMC Vet Res. 2016;12:191.
24. Geburek F, Lietzau M, Beineke A, Rohn K, Stadler PM. Effect of intraligamental desmitis in Standardbred racehorses. J Am Vet Med Assoc. 2008;232:1515–20.
25. McCoy AM, Smith RL, Secor EJ, Roady PJ. Effects of 2 preparation methods and long-term storage on structural integrity and bacterial loads of autologous conditioned serum to treat proximal suspensory desmitis. Proc Am Assoc Equine Pract. 2014;41:516–22.
26. Littwinik M, Grzela T. Amniotic membrane: New concepts for an old dressing. Wound Repair and Regen. 2014;22:451–6.
27. Fortier LA, Smith RKW. Regenerative medicine for tendinous and ligamentous injuries of sport horses. Vet Clin North Am Equine Pract. 2008;24:191–201.
28. McCay AM, Smith RL, Secor EJ, Roady PJ. Effects of 2 preparation methods and long-term storage on structural integrity and bacterial loads of equine amniotic. Vet Surg. 2019;48:222–8.
29. AAEP Lameness Exams: Evaluating the Lame Horse. Available at https://aaep.org/horsehealth/lameness-exams-evaluating-lame-horse.
30. Gutierrez-Nibeyro SD, White NA, Werpy NM, Tyrrell L, Allen KA, Sullins KE, Mitchell RD. Magnetic resonance imaging findings of desmopathy of the collateral ligaments of the equine distal interphalangeal joint. Vet Radiol Ultrasound. 2009;50:21–31.
31. Sampson SN, Schneider RK, Tucker RL, Gavin PR, Zubrod CJ, Ho CP. Magnetic resonance imaging features of oblique and straight distal sesamoid desmitis in 27 horses. Vet Radiol Ultrasound. 2007;48:303–11.
33. Schneider RK, Tucker RL, Habegger SR, Brown J, Leathers CW. Desmitis of the straight sesamoidean ligament in horses: 9 cases (1995–1997). J Am Vet Med Assoc. 2003;222:973–7.
34. Denoix JM, Guizien I, Perrot P, Bousseau B. Ultrasonographic diagnosis of the accessory ligament of the superficial digital flexor tendon (proximal check ligament) in 23 horses. Proc Am Assoc Equine Pract. 1995;41:142–3.
35. Dyson SJ. Normal ultrasonographic anatomy and injury of the patellar ligaments in the horse. Equine Vet J. 2002;34:258–64.
36. Ursini TL, Amelse LL, Elkhennawy HA, et al. Retrospective analysis of local injection site adverse reactions associated with 230 allogenic administrations of bone marrow-derived mesenchymal stem cells in 164 horses. Equine Vet J. 2019;51:198–208.
37. Hyvisc [package insert]. St. Joseph, MO 64506 U.S.A.: Boehringer Ingelheim Vetmedica, Inc.; 2009.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.